Sernova Biotherapeutics Inc.

Dr. Joseph Pantginis, H.C. Wainwright & Co. (6/23/25) "We are encouraged by SVA's interim Phase 1/2 data."

Dr. Andre Uddin, Research Capital Corporation (6/16/25) "Positive Cohort C data could be a value inflection point for SVA."

Dr. Douglas Loe, Leede Financial Inc. (5/23/25) "SVA assembled a clinical advisory board germane to its efforts."

BioLargo Inc.

Richard Ryan, Oak Ridge Financial (5/19/25) "Clyra has a chance to be one of BLGO's most profitable operations."

Sernova Biotherapeutics Inc.

Dr. Douglas Loe, Leede Financial Inc. (5/16/25) "SVA is achieving positive results with both Cell Pouch configurations."

Rakovina Therapeutics Inc.

Dr. Douglas Loe, Leede Financial Inc. (5/16/25) "Gross proceeds from RKV's convertible debenture financing were $2.9M."

Sernova Biotherapeutics Inc.

Dr. Joseph Pantginis, H.C. Wainwright & Co. (5/14/25) "SVA's interim data indicate the T1D trial is on track to succeed."

Dr. Joseph Pantginis, H.C. Wainwright & Co. (4/22/25) "We see opportunity for SVA and Cell Pouch where VX-264 came up short."

Dr. Douglas Loe, Leede Financial Inc. (4/17/25) "SVA just raised CA$4M in new debt capital."

Dr. Douglas Loe, Leede Financial Inc. (4/4/25) "The clinical risk for SVA's Cell Pouch itself is essentially nil at this stage."

Dr. Douglas Loe, Leede Financial Inc. (3/31/25) "The end of Vertex's VX-264 program is on balance positive for SVA."

Dr. Douglas Loe, Leede Financial Inc. (3/3/25) "SVA may proceed with Phase 1 testing of Cell Pouch in thyroid disease."

Dr. Douglas Loe, Leede Financial Inc. (2/3/25) "SVA filed an IND for testing of its Cell Pouch in thyroid disease."

Dr. Joseph Pantginis, H.C. Wainwright & Co. (2/3/25) "SVA's Cell Pouch could become a 'pipeline in a device.'"

Dr. Douglas Loe, Leede Financial Inc. (1/31/25) "SVA added U.S. executive Ross Haghighat to its board."

Dr. Joseph Pantginis, H.C. Wainwright & Co. (1/22/25) "We are encouraged by new data from SVA's trial of Cell Pouch in T1D."

Rakovina Therapeutics Inc.

Dr. Douglas Loe, Leede Financial Inc. (1/17/25) "We are encouraged by advances made by RKV and its partners."

Sernova Biotherapeutics Inc.

Dr. Douglas Loe, Leede Financial Inc. (1/10/25) "Sana/UP421 are plausible partners for SVA and Cell Pouch development."

Dr. Douglas Loe, Leede Financial Inc. (12/6/24) "SVA enters into new alliance in Saudi Arabia for Type 1 diabetes."

Dr. Douglas Loe, Leede Financial Inc. (11/15/24) "SVA partner, Evotec, received a formal bid to be acquired by Halozyme."

Dr. Douglas Loe, Leede Financial Inc. (11/6/24) "SVA's partnership landscape should expand."

Dr. Douglas Loe, Leede Financial Inc. (9/20/24) "SVA's new board member has tech commercialization experience."

Clive Maund, CliveMaund.com (9/12/24) "SVA is considered to be very undervalued here."

Dr. Douglas Loe, Leede Financial Inc. (9/12/24) "SV's Phase 1 update is positive to the Cell Pouch's medical prospects."

Dr. Joseph Pantginis, H.C. Wainwright & Co. (9/12/24) "Efficacy in SV's Cell Pouch trial in type 1 diabetes deepens."

Stefan Quenneville, Ventum Capital Markets (9/12/24) "SV appointed Executive Chairman Jonathan Rigby as CEO."

Reliq Health Technologies Inc.

SADIF Investment Analytics (5/25/23) "RHT has a bright prospect, fair financials and good earnings quality."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (4/24/23) "AGN's stock is silly cheap and so a good investment."

Reliq Health Technologies Inc.

SADIF Investment Analytics (4/3/23) "RHT's stock has been upgraded to Above Average from Average."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (1/27/23) "Updates on Alzheimer's by three biopharmas are pertinent to PMN."

Reliq Health Technologies Inc.

Jefferson Research (1/20/23) "RHT's balance sheet rating improved during Q1/23."

Algernon Pharmaceuticals Inc.

Dr. Douglas Loe, Leede Jones Gable (1/13/23) "AGN plans to initiate a Phase 2b trial of ifenprodil in chronic cough."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (1/6/23) "We expect PMN to commence formal Phase 1 testing later this year."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (12/21/22) "When AGN moves, it is likely to result in big percentage gains."

Reliq Health Technologies Inc.

Jefferson Research (12/15/22) "The valuation for RHT suggests a lower amount of price risk."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (12/1/22) "Data presented by peers at the CTAD conference are relevant to PMN."

Algernon Pharmaceuticals Inc.

Dr. Andre Uddin, Research Capital Corporation (11/30/22) "Positive Phase 2a data were achieved with AGN's ifenprodil."

Reliq Health Technologies Inc.

Clive Maund, CliveMaund.com (11/22/22) "This is a good point to add to positions or make new purchases of RHQ."

Dr. Douglas Loe, Leede Jones Gable (11/4/22) "RHT added 50 new nursing home clients in Florida to its network."

Clive Maund, CliveMaund.com (11/1/22) "The dip of recent days presents us with a better entry point for RHT."

ProMIS Neurosciences Inc.

Steve Silver, Argus Research (10/28/22) "PMN expects to file an NDA for PMN310 with the FDA by 2022E."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (10/24/22) "AGN is rated a Buy again here."

Clive Maund, CliveMaund.com (10/16/22) "AGN is rated an immediate Strong Buy."

ProMIS Neurosciences Inc.

Clive Maund, CliveMaund.com (10/10/22) "This is a good time to buy PMN stock."

Dr. Douglas Loe, Leede Jones Gable (9/30/22) "PMN peer, Eisai, reported positive Phase 3 Alzheimer's disease data."

Dr. Douglas Loe, Leede Jones Gable (9/28/22) "We are positive about PMN's PMN-310 possibly mitigating AD progression."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (9/27/22) "A minor relief rally in the broad market could see AGN shoot up again."

Awakn Life Sciences Corp.

Clive Maund, CliveMaund.com (9/11/22) "AWKNF's exceptionally positive technical setup keeps getting better."

Clive Maund, CliveMaund.com (9/5/22) "AWKNF is a stock that it is thought to be worth going overweight on."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (8/23/22) "The case for buying AGN here could scarcely be stronger."

Clive Maund, CliveMaund.com (8/17/22) "AGN is rated Buy again here."

Awakn Life Sciences Corp.

Clive Maund, CliveMaund.com (8/16/22) "AWKN is now in position to break out into a new bull market."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (8/15/22) "AGN has the capacity to make really big moves."

Awakn Life Sciences Corp.

Andrew Partheniou, Stifel (8/15/22) "AWKN announced its first KARE licensing agreement."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (8/5/22) "Experiments showed that PMN's PMN310 has a unique binding profile."

Algernon Pharmaceuticals Inc.

Dr. Andre Uddin, Research Capital Corporation (7/28/22) "It would be logical for AGN to develop ifenprodil for two indications."

Clive Maund, CliveMaund.com (7/28/22) "AGN is considered to be at another good buy spot here."

Dr. Andre Uddin, Research Capital Corporation (7/18/22) "In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

Reliq Health Technologies Inc.

Jefferson Research (7/14/22) "RHT's quality of net income earnings is extremely high."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (7/6/22) "PMN's PMN310 could benefit from favorable FDA review of lecanemab."

Steve Silver, Argus Research (7/6/22) "PMN designated PMN267 as its lead candidate for treatment of ALS."

Awakn Life Sciences Corp.

Patrick Trucchio, H.C. Wainwright & Co. (6/30/22) "AWKNF's key programs are on track."

ProMIS Neurosciences Inc.

Steve Silver, Argus Research (6/27/22) "PMN's PMN310 potentially represents a best-in-class opportunity."

Reliq Health Technologies Inc.

Jefferson Research (6/10/22) "RHT is showing strong earnings quality and cash flow quality."

Avivagen Inc.

Joseph Gomes, Noble Capital Markets (6/3/22) "VIV has signed a new distribution agreement with Nong San Viet Co."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (6/1/22) "AGN looks like it is shaping up for a breakout into a new bull market."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (5/11/22) "We are initiating coverage on PMN with a Speculative Buy rating."

Awakn Life Sciences Corp.

Patrick Trucchio, H.C. Wainwright & Co. (5/2/22) "AWKNF's KARE program is on track to advance to Phase 3 in H2/22."

Reliq Health Technologies Inc.

Clive Maund, CliveMaund.com (4/26/22) "RHT is rated an Immediate Buy here."

ProMIS Neurosciences Inc.

Steve Silver, Argus Research (4/13/22) "We view PMN's path to clinical value inflection favorably."

Awakn Life Sciences Corp.

Andrew Partheniou, Stifel (3/31/22) "AWKNF shares offer an attractive risk-reward profile."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (2/2/22) "AGN has reacted back satisfactorily to another good buy spot."

Awakn Life Sciences Corp.

Patrick Trucchio, H.C. Wainwright & Co. (2/1/22) "AWKNF's R&D is focused on advancing therapies to treat addictions."

Avivagen Inc.

David Bautz, Zacks Small-Cap Research (1/31/22) "Sales of VIV's OxC-beta should begin to increase throughout 2022."

Algernon Pharmaceuticals Inc.

Dr. Andre Uddin, Research Capital Corporation (1/28/22) "AGN's current valuation is favorable from a risk-reward standpoint."

Avivagen Inc.

Joseph Gomes, Noble Capital Markets (1/27/22) "VIV is at an inflection point with sales increases around the corner."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (1/19/22) "As we can see on its latest six-month chart, AGN's stock has soared."

Bob Moriarty, 321 Gold (1/18/22) "AGN has a lot of potential, and I placed my bet with shares bought."

Stem Holdings Inc.

Joseph Gomes, Noble Capital Markets (1/18/22) "STEM reported net FY21 revenue of $35.8M versus $14M last year."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (1/12/22) "After a 1 for 100 rollback, AGN has big upside potential."